Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 71

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 71
---
 financial condition of either TELI or TELI.                                     |

TELI Capitalization on Closing

TELI shall have assets comprising any combination of cash and marketable securities with a total value of at least one million U.S. dollars (US$1,000,000).

Certain major shareholders of TELI (including Bayshore Trust and related parties) shall agree in advance to contribute an amount of assets or cash (or a combination of the two) totaling up to $5,000,000 to Telomir, with $1,000,000 due at closing, $2,000,000 due upon IND acceptance by the FDA, and $2,000,000 due upon initiation of Phase 1/2. For purposes of determining the exchange ratio, the valuation of TELI does not include the full $5,000,000 cash contribution. The actual payments of such amounts following the milestone is not a condition to the closing of the Merger.

Approvals

The Board of Directors of TELO has unanimously approved the Merger Agreement and recommends that shareholders of TELO approve the Merger. Similarly, the Board of Directors of TELI has approved the Merger and recommends that its shareholders vote “FOR” the issuance of shares in connection with the Merger.

Termination

The Merger Agreement provides for termination under certain circumstances, including:

| ● 
 ● 
 ● | Mutual                                                                       
 written consent of TELO and TELI                                             
 Failure                                                                      
 to obtain shareholder approval by TELI and by TELI;                          
 If                                                                           
 the Closing has not occurred by December 31, 2025;                           |
|:--|:-----------------------------------------------------------------------------|
| ● | If                                                                           
 a Governmental Entity has issued a final ruling prohibiting the Closing; and |
| ● | By                                                                           
 one party upon an uncured breach of the Merger Agreement by the other party. |

Treatment of TELI Stock Options

TELI currently has no stock options outstanding.

Treatment of TELI Warrants

Under the terms of the Merger Agreement, each warrant to purchase shares of TELI Common Stock that is outstanding will be converted into and become a warrant to purchase shares of TELO Common Stock and TELO will assume each TELI warrant in accordance with its terms. In addition to the Merger Share Consideration, certain members of TELI collectively hold warrants to purchase a total of 14,250,000 TELI Common Stock (the “Warrants”). The W